| 0.8898 0.033 (3.82%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.2 | 1-year : | 1.34 |
| Resists | First : | 1.02 | Second : | 1.14 |
| Pivot price | 0.91  |
|||
| Supports | First : | 0.83 | Second : | 0.69 |
| MAs | MA(5) : | 0.86  |
MA(20) : | 0.94 |
| MA(100) : | 1.08 |
MA(250) : | 1.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.9 |
D(3) : | 13 |
| RSI | RSI(14): 38.7 |
|||
| 52-week | High : | 1.81 | Low : | 0.83 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PLRX ] has closed above bottom band by 37.7%. Bollinger Bands are 68.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.89 - 0.9 | 0.9 - 0.9 |
| Low: | 0.83 - 0.84 | 0.84 - 0.84 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Fri, 23 Oct 2026
Pliant Therapeutics, Inc. Estimates – NASDAQ:PLRX - TradingView
Tue, 20 Oct 2026
Pliant Therapeutics Appoints Craig Blanchette as SVP to Advance siRNA Research - citybiz
Tue, 20 Oct 2026
Pliant Therapeutics appoints Craig Blanchette as SVP, Research - Investing.com
Tue, 20 Oct 2026
A researcher turned a drug platform into three programs. Now he joins Pliant. - Stock Titan
Mon, 19 Oct 2026
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - GlobeNewswire
Wed, 19 Aug 2026
Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 78.1 (%) |
| Shares Short | 4,250 (K) |
| Shares Short P.Month | 3,280 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|